Table 1.
Characteristics of the 106 patients included in the study
| Characteristics at HAART initiation | ||
| Women, number (%) | 63 | (59%) |
| Including with history of pMTCT* | 16 | (25%) |
| Age in years, median (IQR) | 38 | (33–44) |
| Antiretroviral dual therapy before HAART initiation (number, %) | 7 | (7%) |
| Type of HIV seropositivity, number (%) | ||
| HIV-1 | 101 | (95%) |
| Dual HIV-l&2 | 5 | (5%) |
| Nadir of CD4+ cell count/mm3, median (IQR) | 122 | 58–226 |
| Body mass index in kg/m3, median (IQR) | 20.5 | (18.5–22.7) |
| WHO clinical stage III or IV, number (%) | 96 | (91%) |
| Past history of tuberculosis, number (%) | 15 | (14%) |
| Initial HAART regimen**, number (%) | ||
| 2 NRTIs + 1 PI | 61 | (58%) |
| 2 NRTIs + 1 NNRTI | 37 | (35%) |
| Others | 8 | (8%) |
| Characteristics at inclusion in the study | ||
| Previous time on HAART in months, median (IQR) | 37.4 | (27.2–48.3) |
| Drug regimen change since HAART initiation, number (%) | ||
| None | 40 | (38%) |
| Patients with one change | 27 | (25%) |
| Patients with ≥ 2 changes | 39 | (37%) |
| CD4+ cell count/mm3, median (IQR) | 266 | (159–407) |
| Body mass index in kg/m2, median (IQR) | 21.6 | (19.8–24.7) |
| WHO clinical stage III or IV, number (%) | 100 | (94%) |
| Past history of tuberculosis, number (%) | 25 | (24%) |
| Current HAART regimen***, number (%) | ||
| 2 NRTIs + 1 PI | 56 | (53%) |
| 2 NRTIs + 1 NNRTI | 47 | (45%) |
| Others | 2 | (2%) |
| Virological status | ||
| Undetectable viral load, number, (%) | 62 | (58%) |
| Detectable viral load, number (%) | 44 | (42%) |
| With ≥ 1 major mutations | 23 | (21%) |
| With no major mutations | 21 | (20%) |
| Follow-up after inclusion in the study | ||
| Follow-up time in months, median (IQR) | 20.5 | (19.7–21.1) |
| At least one serious clinical event during follow-up, number (%) | 29 | (27%) |
| Characteristics at study termination | ||
| CD4+ cell count/mm3, median (IQR) | 338 | (214–519) |
| Status, number (%) | ||
| Deceased | 1 | (1%) |
| Lost to follow-up | 1 | (1%) |
| Alive and in active follow-up | 104 | (98%) |
IQR: interquartile range;
HAART: highly active antiretroviral therapy;
NRTI: nucleoside reverse transcriptase inhibitor;
NNRTI: non-nucleoside reverse transcriptase inhibitor;
PI: protease inhibitor.
Viral load: plasma HIV-1 RNA level
WHO: World Health Organisation
*
pMTCT: prevention of mother-to-child transmission of HIV infection: ZDV (n=14), ZDV+NVP (n=l), d4T+3TC+NFV (n=l).
**
NRTIs: 3TC (n=76), ZDV (n=61), d4T (n=45), ddI (n=29), ddC (n=1); NNRTI: EFV (n=37); PI: IDV (n=30), NFV (n=29), SQV (n=2).
***
NRTIs: 3TC (n=79), ZDV (n=55), d4T (n=51), ddI (n=28); NNRTI: EFV (n=47); PI: IDV (n=29), NFV(n=28)